NBD AI Bulletin,Tianjin Chase Sun Pharmaceutical Co., Ltd. (the Company, SZ 300026, closing price: 5.29 yuan) issued an announcement on the evening of Thursday that its deputy general manager Gao Guowei and one of his family member opened their securities accounts in the same securities company, which only differ in one number. On June 3, 2020, the family member mistakenly entered Gao's securities account without notifying him, and unloaded 100,000 shares of the Company at an average transaction price of 5.5 yuan. Gao's failure to report to the Shenzhen bourse and disclose the share reduction plan 15 trading days prior to the sale constitutes a breach of the unloading rules.

According to its 2019 Annual Report, Tianjin Chase Sun Pharmaceutical Co., Ltd. mainly engages in TCM formulation (particles and decoction pieces), finished medicines, medical devices, and active ingredient & supplementary material-related businesses, accounting for 54.09%, 21.2%, 13.09% and 8.44% of its revenue, respectively.

Tianjin Chase Sun Pharmaceutical Co., Ltd. is chaired by Yao Xiaoqing, a 55-years-old medical practitioner with a Doctoral degree and no permanent overseas residency. Tianjin Chase Sun Pharmaceutical Co., Ltd.'s general manager is Zheng Dan, a 56-years-old Chinese national with a Master's degree and no permanent overseas residency.

(By Tan Yuhan)

(By Tan Yuhan)

Disclaimer: This article is for informational purposes only and does Not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.